Hillstream BioPharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HILS research report →
Price Chart
About the company
Hillstream BioPharma, Inc. is a pre-clinical stage biotechnology firm committed to creating groundbreaking therapeutic options. Its core mission is to exploit ferroptosis, an anti-cancer pathway that initiates iron-mediated cell death (IMCD), specifically to address cancers that are resistant to conventional treatments.
- CEO
- Randy D. Milby MBA
- IPO
- 2022
- Employees
- 1
- HQ
- Bridgewater, NJ, US
Get TickerSpark's AI analysis on HILS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.17M
- P/E
- -0.16
- PEG
- -0.00
- P/S
- 2.79
- P/B
- 0.11
- EV/EBITDA
- 0.62
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- -3595.17%
- Net Margin
- -6559.27%
- ROE
- -29.54%
- ROIC
- -8.14%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-20,106,066
- Net Income
- $-35,916,250-194.5%
- EPS
- $-1.12+88.1%
- OCF Growth
- -47.9%
- FCF Growth
- -47.9%
- 52W High
- $2.65
- 52W Low
- $0.17
- 50D MA
- $0.25
- 200D MA
- $0.58
- Beta
- 0.00
- RSI (14)
- 41
- Avg Volume
- 684.78K
No earnings-call transcripts are available for HILS yet.
- Free Float
- 65.1%
- Shares Outstanding
- 17.60M
- Float Shares
- 11.46M
of shares held by institutions
7 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 3 ETFs
Biggest fund positions in HILS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 15, 23 | MILBY RANDY | buy | 29,000 |
| Nov 30, 23 | MILBY RANDY | buy | 10,000 |
| Nov 7, 23 | Bui Lynne A. | other | 25,000 |
| Nov 7, 23 | Appajosyula Sireesh | other | 25,000 |
| Nov 7, 23 | Anderson Kelly | other | 50,000 |
| Nov 7, 23 | Mazur Leonard L | other | 25,000 |
| May 9, 23 | Anderson Kelly | other | 0 |
| Jan 1, 23 | MILBY RANDY | other | 515,127 |
| Jan 1, 23 | MILBY RANDY | other | 621,795 |
| Jul 14, 22 | Appajosyula Sireesh | other | 75,757 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HILS coverage
Recent articles, reports, and earnings notes.
No research on HILS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HILS report →Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl
globenewswire.com · Sep 4
Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.
accesswire.com · Sep 22
Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis
globenewswire.com · Sep 11
Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13
globenewswire.com · Sep 8
Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023
globenewswire.com · Aug 9
Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215
globenewswire.com · Jul 20
Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics
globenewswire.com · Jul 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.